
Modified GRF (1-29)
CJC-1295 without DAC
- 2mg
- 5mg
For laboratory research use only. Not for human or veterinary use. Not a medicine, food supplement or cosmetic.

Also known as CJC-1295 DAC
Research use only. Not for human or veterinary use. Not a medicine, food supplement or cosmetic.
WADA notice. This compound is on the World Anti-Doping Agency Prohibited List. It is supplied for laboratory research and must not be used in sport.
Batch certificates are moving here from the old Quality Centre. To get the CoA for the batch you would receive today, email [email protected] with the SKU.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered for extended half-life through albumin binding. It’s designed to stimulate prolonged release of endogenous growth hormone (GH) and insulin-like growth factor 1 (IGF-1), with a markedly longer half-life than unmodified GHRH analogues. Supplied as a lyophilised powder for research use only, it serves as a powerful tool in studies of hormone axis regulation, tissue metabolism, and recovery pathways.
CJC-1295 with DAC maintains elevated GH and IGF-1 levels for multiple days post-administration, supporting investigations into sustained anabolic signaling and endocrine feedback regulation.
As a modified GHRH analog, it binds the GHRH receptor in the anterior pituitary to drive GH secretion in a controlled, sustained manner—ideal for research into hormonal cascade dynamics.
Researchers explore its utility in examining changes in lean mass, fat metabolism, and tissue remodeling through GH/IGF-1 mediated pathways.
CJC-1295 with DAC contrasts sharply with the non-DAC form in half-life—an important variable in experimental design considering temporal hormone dynamics and receptor feedback.
CJC-1295 with DAC is a robust research peptide for modeling prolonged endogenous GH/IGF-1 axis activation. It offers a controlled system for studying anabolic pathways, endocrine signaling, and metabolic regulation. Supplied strictly for research use only, it is not intended for human or veterinary application.
• Synonyms: CJC-1295 DAC; DAC:GRF (Drug Affinity Complex–GHRH analog)
• Modified Single-Letter Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
• IUPAC Condensed Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
• Molecular Weight: ~3648 g/mol
• CAS Number: 446262-90-4
• PubChem CID: 56841945
• Further Reference: PubChem Link
• Stability: Stable up to 36 months when stored at –20 °C or colder, protected from light and moisture.
• Source: Synthesized using solid-phase peptide methods and supplied with Certificate of Analysis (COA) confirming purity and identity.
• Reconstitution: Dissolve in sterile water or PBS under aseptic conditions; aliquot and store at –80 °C following reconstitution to minimize degradation.
• Usage: Product is prepared for LABORATORY RESEARCH ONLY. Intended for controlled in-vitro and in-vivo laboratory protocols.

CJC-1295 without DAC





